Aravt Global’s Impax Laboratories, Inc. IPXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q3
Sell
-2,232,500
Closed -$64.3M 20
2016
Q2
$64.3M Sell
2,232,500
-839,378
-27% -$27.4M 4.78% 9
2016
Q1
$98.4M Hold
3,071,878
8.33% 3
2015
Q4
$131M Sell
3,071,878
-373,122
-11% -$14.9M 13.28% 1
2015
Q3
$121M Buy
3,445,000
+445,000
+15% +$20M 10.39% 3
2015
Q2
$138M Buy
3,000,000
+330,000
+12% +$15.7M 11.01% 2
2015
Q1
$125M Buy
2,670,000
+370,000
+16% +$14.7M 9.4% 1
2014
Q4
$72.9M Buy
+2,300,000
New +$67.3M 5.43% 9

Other funds holding IPXL

Aravt Global's IPXL Position: Q3 2016 in Review

Aravt Global sold out of Impax Laboratories, Inc. (IPXL) in Q3 2016, closing a stake of 2,232,500 shares — an estimated $64.3M sold.

Aravt Global first reported a position in IPXL in Q4 2014 and held it in 7 quarters. The position peaked at $138M in Q2 2015. 196 funds tracked by Wall St. Rank hold IPXL as of Q3 2016.

  • Aravt Global reported no remaining Impax Laboratories, Inc. position as of Q3 2016 after selling out during the quarter.
  • Aravt Global sold 2,232,500 Impax Laboratories, Inc. shares in Q3 2016, an estimated $64.3M.
  • Aravt Global first reported a position in Impax Laboratories, Inc. in Q4 2014 and held it in 7 quarters.
  • Aravt Global's Impax Laboratories, Inc. position peaked at $138M in Q2 2015.
  • 196 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2016.

Based on Aravt Global's 13F filing for Q3 2016, filed 14 Nov 2016.